S&C Advises Integra LifeSciences in Acquisition of Regenerative Medicine Company ACell

February 3, 2021

Integra LifeSciences Holdings Corporation completed its acquisition of ACell Inc. on January 20 for an upfront cash payment of $300 million and additional cash payments of up to $100 million upon the achievement of certain revenue growth milestones.

Integra LifeSciences is a global leader in medical technology, offering innovative solutions, including leading regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies.

ACell is an innovative regenerative medicine company with a product portfolio based on a proprietary porcine urinary bladder matrix platform technology, MatriStem UBMTM. The acquisition of ACell is the next step in the expansion of Integra's Orthopedics and Tissue Technologies segment.

The S&C team advising on M&A matters was led by Melissa Sawyer and included associates Benjamin Goodchild and Beini Chen. Davis Wang advised on tax matters; Heather Coleman advised on executive compensation; Mehdi Ansari advised on intellectual property matters; Renata Hesse advised on antitrust matters; special counsel Eric Queen advised on HSR matters; and special counsel Matt Brennan advised on representation and warranty insurance matters.